Angioimmunoblastic T cell lymphoma: Pathobiological insights and clinical implications

Current Opinion in Hematology

Volumn 14, Issue 4, 2007, Pages 348-353

  Dunleavy, Kieron ^a   Wilson, Wyndham H ^a   Jaffe, Elaine S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemokines; Epstein Barr virus; Immunoregulation; Peripheral T cell lymphoma; T cells

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; BEVACIZUMAB; CHEMOKINE; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VINCRISTINE;

B CELL LYMPHOMA; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE OVEREXPRESSION; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MULTIPLE MYELOMA; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; T CELL LYMPHOMA;

HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL, PERIPHERAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249732055     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328186ffbf     Document Type: Review

References (48)

1. Jaffe E, Harris N, Stein H, Vardiman J. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon. IARC Press; 2001.
2. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2006; 317-322. Review that discusses the pathophysiology of T cell subsets and the classification of T cell and natural killer cell lymphomas.
3. Greer JP. Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 2006; 331-337. Review of the current therapy of peripheral T and natural killer cell lymphoproliferative disorders.
4. Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32:545-552.
5. Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 1999; 23:1233-1240.
6. Zettl A, Lee SS, Rudiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002; 117:368-379.
7. Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 1993; 82:241-246.
8. Ree HJ, Kadin ME, Kikuchi M, et al. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. Am J Surg Pathol 1998; 22:643-655.
9. Kim CH, Lim HW, Kim JR, et al. Unique gene expression program of human germinal center T helper cells. Blood 2004; 104:1952-1960.
10. Dunleavy K, Wilson W. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk Lymphoma 2007; in press.
11. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006; 30:490-494. Authors investigate CXCL13 expression in AILT and other T cell lymphomas; CXCL13 was highly expressed in all cases of AILT.
12. Grogg KL, Attygale AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006; 19:1101-1107. Authors investigate CXCL13 expression in AILT, other T cell lymphomas and reactive lymph nodes. CXCL13 was highly associated with AILT.
13. FH cells.
14. Kanemitsu N, Ebisuno Y, Tanaka T, et al. CXCL13 is an arrest chemokine for B cells in high endothelial venules. Blood 2005; 106:2613-2618.
15. Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 2006; 8:466-475; quiz 527. Study that examines the frequency of B and T cell gene rearrangements and correlation with EBV in a series of AILT and PTCL-u.
16. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974; 1:1070-1073.
17. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med 1975; 59:803-818.
18. Weiss L, Strickler J, Dorfman R, et al. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 1986; 122:392-397.
19. Lennert K, Feller A. Histopathology of non-Hodgkin's lymphomas. 2 ed. New York: Springer; 1992.
20. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89-94.
21. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330:1267-1271.
22. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80:1804-1812.
23. Smith JL, Hodges E, Quin CT, et al. B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy. Am J Pathol 2000; 156:661-669.
24. Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79:1789-1795.
25. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 2005; 49:285-292.
26. Widney D, Boscardin WJ, Kasravi A, Martinez-Maza O. Expression and function of CD28 on Epstein-Barr virus-positive B cell lines and AIDS-associated non-Hodgkin's lymphoma cell lines. Tumour Biol 2003; 24: 82-93.
27. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005; 79:4896-4907.
28. Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 2006; 33:596-606.
29. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004; 84:1512-1519.
30. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94:3717-3721.
31. De Bont ES, Fidler V, Meeuwsen T, et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002; 8:2856-2861.
32. Koomagi R, Zintl F, Sauerbrey A, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001; 7:3381-3384.
33. FH cells.
34. Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117:364-370.
35. Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995; 6:659-664.
36. Hast R, Jacobsson B, Petrescu A, Hjalmar V. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 1999; 34:597-601.
37. Jantunen E, D'Amore F. Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma 2004; 45:441-446.
38. Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88:1272-1278.
39. Advani R, Horwitz S, Zelenetz A, Horning S. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lympohoma 2007; in press.
40. Siegert W, Nerl C, Meuthen I, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia 1991; 5:892-895.
41. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005; 19:1993-1995. Case-report of a complete remission to bevacizumab in a patient with relapsed AILT.
42. Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 2005; 19:873-875.
43. Halene S, Zieske A, Berliner N. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol 2006; 3:165-168; quiz 9.
44. Ramasamy K, Lim Z, Pagliuca A, et al. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 2006; 91 (8 Suppl):ECR44.
45. Joly B, Frenkel V, Gaulard P, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL). Preliminary results in 9 patients treated in a single institution [abstract]. Blood 2005; 106:106.
46. Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24:718-725.
47. Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H. Thalidomide in multiple myeloma. Curr Pharm Biotechnol 2006; 7:431-440.
48. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-1802.